GC
AMLX icon

Guggenheim Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Guggenheim Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$456K Sell
25,387
-126
-0.5% -$1.95K ﹤0.01% 1324
2026
Q1 		$355K Buy
25,513
+270
+1% +$3.8K ﹤0.01% 1321
2025
Q4 		$305K Buy
25,243
+344
+1% +$4.67K ﹤0.01% 1522
2025
Q3 		$338K Sell
24,899
-10,853
-30% -$102K ﹤0.01% 1349
2025
Q2 		$229K Sell
35,752
-2,044
-5% -$9.94K ﹤0.01% 1468
2025
Q1 		$134K Buy
37,796
+1,928
+5% +$6.86K ﹤0.01% 1583
2024
Q4 		$136K Buy
35,868
+20,470
+133% +$96.3K ﹤0.01% 1639
2024
Q3 		$49.9K Sell
15,398
-50
-0.3% -$112 ﹤0.01% 1848
2024
Q2 		$29.4K Sell
15,448
-890
-5% -$1.73K ﹤0.01% 1854
2024
Q1 		$46.4K Buy
16,338
+1,392
+9% +$18.2K ﹤0.01% 1862
2023
Q4 		$220K Buy
+14,946
New +$229K ﹤0.01% 1781

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Guggenheim Capital's AMLX Position: Q2 2026 in Review

Guggenheim Capital reduced its Amylyx Pharmaceuticals (AMLX) stake by 0.49% in Q2 2026, selling an estimated $1.95K and leaving 25,387 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #1324.

Guggenheim Capital first reported a position in AMLX in Q4 2023 and has held it in 11 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Guggenheim Capital held 25,387 shares of Amylyx Pharmaceuticals worth $456K as of Q2 2026.
  • Guggenheim Capital sold 126 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.95K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1324 holding.
  • Guggenheim Capital first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.